I
n Taiwan, renal cell carcinoma (RCC) accounts for 1% of all cancer cases. Approximately, 800 patients are newly diagnosed with RCC annually. The incidence rate per 100,000 person-years was 3.1% in 2008.
(1) RCCs arise from the proximal renal tubules, and approximately 85% are the clear cell type. When patients with RCC present with localized disease, surgical resection remains the only known curative treatment. Unfortunately, one-third of the patients with resectable localized disease will eventually relapse. (2) Furthermore, 20% -30% of patients have metastatic disease at diagnosis, and the 5-year survival for patients with metastatic disease is less than 10%.
Cytokines (i.e., interferon-α and interleukin 2) were the mainstay of treatment for advanced RCC before the development of targeted therapies. In recent years, an understanding of the pathogenesis of RCC has aided in elucidating the critical role of the von Hippel-Lindau (VHL) tumor suppressor gene. Several agents that target the vascular endothelial vascular growth factor (VEGF) pathway and the mammalian target of rapamycin (mTOR) pathway have proven significantly effective against this disease. (3, 4) Everolimus (Afinitor; Novartis, U.S.A.), an orally administered mTOR inhibitor, has been studied as an immunosuppressant for solid organ transplantation. (5) In a Phase I trial for the safety evaluation of the daily dosing of everolimus (up to 10 mg), one patient with RCC was found to have a confirmed partial response. (6) A single-arm phase II trial that enrolled 41 RCC patients reported a median progression-free survival (PFS) and a median overall survival (OS) of 11.2 and 22.1 months, respectively, and 70% of the patients achieved either a tumor response or disease stabilization for 6 months or more. (7) The pivotal Phase III trial, the Renal Cell cancer treatment with Oral RAD001 given Daily (RECORD)-1 trial, randomized 410 patients with advanced RCC to either everolimus 10 mg daily or placebo groups. (8) All patients exhibited a clear cell histology type that had progressed within 6 months of therapy with the VEGF receptor tyrosine kinase inhibitors (VEGFR-TKI) sunitinib, sorafenib, or both. The median PFS in the everolimus group was significantly prolonged compared with that in the placebo group (4.9 versus 1.9 months; hazard ratio [HR] 0.30, p < 0.001). The lack of a significant difference in the median OS between the everolimus and placebo groups in the final survival analysis could be attributed to the effects of crossover. The overall objective responses (ie, complete and partial responses) were quite low (1% and 0% with everolimus and placebo, respectively), while disease stabilization was more common (66% and 32% with everolimus and placebo, respectively). Everolimus is considered the standard treatment for patients with advanced RCC after failure of sorafenib or sunitinib. However, there is still limited experience with regard to the efficacy of everolimus in the treatment of RCC in Taiwan. Here we present our experience with everolimus in metastatic RCC (mRCC) at Chang Gung Memorial Hospital in Taiwan.
METHODS
The study was reviewed and approved by the Institutional Review Board of Chang Gung Memorial Hospital. (IRB No.: 100-3178B). Twentyfour patients with pathologically diagnosed RCC who were treated with everolimus after disease progression or intolerability with at least one VEGFR-TKI between March 2009 and August 2011 were enrolled. Patients were required to have adequate bone marrow function (absolute neutrophil count ≥ 1.5 x 10 9 /L, hemoglobin ≥ 9 g/dL, platelet count ≥ 100 x 10 9 /L), hepatic function (serum total bilirubin ≤ 1.5 mg/dL, aspartate transaminase or alanine transaminase ≤ 70 IU/L), and renal function (serum creatinine ≤ 2 mg/dL). Medical records, laboratory data, chest radiographs, bone scans and computed tomography scans were retrospectively reviewed. All enrolled patients received oral everolimus 10 mg daily until disease progression or the occurrence of severe adverse events. Under the physician's judgment, the dose was either delayed or reduced to 5 mg/day if the patient had a severe adverse hematological event or other adverse event related to everolimus. Tumor response was assessed periodically according to the Response Evaluation Criteria in Solid Tumors criteria using computed tomography scans and bone scans. The clinical benefit rate was defined as the percentage of patients who had either a partial response or disease stabilization as the best response at any time during treatment. PFS was calculated from the start of everolimus treatment to the time of radiographic progression or death. Survival was calculated from the start of everolimus treatment to death or August 31, 2011, which was the cutoff date for follow-up. Patients who were alive on August 31, 2011 were censored from the analysis. Adverse events were estimated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). Descriptive statistics and frequency counts were used to summarize the characteristics of the study population. The median PFS and OS were estimated using the Kaplan-Meier method. The statistical software SPSS 17.0 (SPSS, Inc., Chicago, IL, U.S.A.) was used for statistical analyses.
RESULTS

Patient and baseline characteristics
A total of 24 patients with RCC were enrolled in the study. Of these, 20 patients (83.4%) demonstrated clear cell histology, and 2 patients each (8.3%) showed the papillary cell and chromophobe histology. Table 1 shows patient and baseline characteristics. Patients had a mean age of 54.8 years; 58.3% were males. All patients were relatively active with an Eastern Cooperative Oncology Group performance status of ≤ 2. Fourteen patients (59%) had a history of previous immunotherapy, and 13 patients (54.9%) had been previously treated with sorafenib alone. After applying the Memorial Sloan-Kettering Cancer Center prognostic score, 17 patients (70.9%) were determined to be at intermediate risk. All patients were treated with everolimus; the mean duration of treatment was 169 days.
Efficacy
As of the cutoff date, no complete or partial responses were noted. Fifteen patients (62.5%) were determined to have stable disease, while disease progression was observed in 5 patients (20.8%) ( Table  2) . Disease response could not be assessed in four patients, two who died shortly before image evaluation and two who had not yet undergone a CT scan before the cutoff date. There were 9 deaths (37.5%) during the follow-up period. Kaplan-Meier analysis showed that the median PFS was 7.1 months (95% confidence interval [CI], 3.6-10.5 months) (Fig. 1) and the median OS was 20.7 months (95% CI, 5.0-36.4 months) (Fig. 2) .
Safety
As summarized in Table 3 , anemia (70.8%), mucositis (54.2%), and rash (45.8%) were the most common adverse events among patients on everolimus therapy. Most adverse events were mild (Grade 1) to moderate (Grade 2) in intensity. Twenty-five percent of the patients showed increased alkaline phosphatase levels; of these, Grades 3/4 levels were reported in 8.3% of patients. Similarly, raised AST levels of Grades 1/2 were observed in 20.5% of patients. Metabolic profiles were available for some patients, and lipid disturbances such as hypercholesterolemia and hypertriglyceridemia of Grades 1/2 were observed in 66.7% and 65% of these patients, respectively. Fifty percent of the patients with available blood sugar data were diagnosed with hyperglycemia; of these, Grades 3/4 levels were noted in 16.7% patients.
DISCUSSION
In the present study, the clinical benefit rate of everolimus treatment following sorafenib and/or sunitinib failure was 62.5%. There was only one patient with a minimal response rather than a partial response. The median PFS and OS after everolimus treatment were 7.1 months and 20.7 months, respectively. The most common non-hematologic toxicities were mucositis, rash and epistaxis.
A Phase III (RECORD-1) trial confirmed the clinical efficacy of everolimus in patients with mRCC who failed initial VERFR-TKI therapy. (8) In the RECORD-1 trial, the partial response rate and clinical benefit rate were 1% and 68.6% (190/277), respectively. Recently, the RAD001 Expanded Access Clinical Trial (REACT) in RCC study was primarily designed to evaluate the long-term toxicity of everolimus in a broader and more heterogeneous patient population. (9) The partial response rate and clinical benefit rate in the REACT study were 1.7% and 53.3%, respectively. In one subgroup analysis of the Japanese population from the RECORD-1 study, the clinical benefit rate was 93.3% (14/15). However, the result may be vulnerable to the small sample size. (10) Our report showed a consistent tumor response in Taiwanese patients.
The median PFS and OS in our study were 7.1 months and 20.7 months, respectively, which were similar to the subgroup analysis of the Japanese population. The longer median PFS and OS in our study compared with the results of the RECORD-1 study may be partly attributed to the better baseline characteristics and longer interval of computed tomography follow-up in our study. Furthermore, the median OS in our study could have been substantially influenced by the length of the follow-up time.
The common adverse events related to everolimus were similar to those reported in the Japanese population from the RECORD-1 trial. (10) Mucositis, rash and epistaxis were the common adverse events, with a frequency of more than 10%. In our study, the overall incidence of non-infectious pneumonitis, a known class effect of rapamycin and its derivatives, was 16.4%. The frequency was similar to that observed in the RECORD-1 study (14%). (8) Although the frequency of non-infectious pneumonitis in the Japanese population was 27%, all cases were manageable. The majority of adverse events were mild. In the REACT study with a more heterogeneous and broader patient population, everolimus was generally well tolerated without any long-term toxicity. Our findings were consistent with those of the REACT study.
The efficacy of everolimus in patients with RCC with a histology type other than the clear cell type has rarely been addressed. The RECORD-1 study enrolled patients with only the clear cell type. In the REACT study, 5.5% of the patients had a histology type other than clear cell, however, the response analysis of these patients was not described. (9) In our study, 2 patients had papillary cell carcinoma and 2 had the chromophobe type. Three of these patients achieved disease stabilization as the best response to everolimus treatment, while the other patient could not be followed up long enough to assess the response.
In conclusion, everolimus is consistently effective and safe in Taiwanese patients with mRCC after failure of VEGFR-TKI therapy. The clinical benefit rate was approximately 62.5% with a non-inferior median PFS and OS. Toxicity related to everolimus is well tolerated and manageable. 
